Marked acceleration of atherosclerosis after lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 8, 2012, Pages

  Chen, Shuang ^a   Lee, Youngho ^a   Crother, Timothy R ^a   Fishbein, Michael ^b   Zhang, Wenxuan ^a   Yilmaz, Atilla ^c   Shimada, Kenichi ^a   Schulte, Danica J ^a   Lehman, Thomas J A ^d   Shah, Prediman K ^e   Arditi, Moshe ^a,e  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d Cornell University ^*  (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; coronary disease; IL 1 receptor antagonist; interleukin 1 beta; Kawasaki disease; mouse model of Kawasaki; vasculitis

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P40; LACTOBACILLUS CASEI EXTRACT; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SINUS; ARTERITIS; ARTICLE; ATHEROSCLEROSIS; BACTERIAL CELL WALL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DENDRITE; FOAM CELL; HYPERCHOLESTEROLEMIA; LIPID DIET; MACROPHAGE; MALE; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VASCULITIS;

ANIMALS; APOLIPOPROTEINS E; ARTERITIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LACTOBACILLUS CASEI; MICE; MICE, INBRED C57BL; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL;

EID: 84864289759     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.249417     Document Type: Article

References (60)

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-276.
2. Burns JC. Kawasaki Disease update. Indian J Pediatr. 2009;76:71-76.
3. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379-1385. (Pubitemid 26307269)
4. Gordon JB, Kahn AM, Burns JC. When children with kawasaki disease grow up myocardial and vascular complications in adulthood. J Am Coll Cardiol. 2009;54:1911-1920.
5. Fukazawa R. Long-term prognosis of Kawasaki disease: increased cardiovascular risk? Curr Opin Pediatr. 2010;22:587-592.
6. Senzaki H. Long-term outcome of Kawasaki disease. Circulation. 2008;118:2763-2772.
7. Gupta-Malhotra M, Gruber D, Abraham SS, Roman MJ, Zabriskie JB, Hudgins LC, Flynn PA, Levine DM, Okorie U, Baday A, Schiller MS, Maturi J, Meehan D, Dyme J, Parker TS, Wittkowski KM, Gersony WM, Cooper RS. Atherosclerosis in survivors of Kawasaki disease. J Pediatr. 2009;155:572-577.
8. Hong YM. Atherosclerotic cardiovascular disease beginning in childhood. Korean Circ J. 2010;40:1-9.
9. Paredes N, Mondal T, Brandão LR, Chan AK. Management of myocardial infarction in children with Kawasaki disease. Blood Coagul Fibrinolysis. 2010;21:620-631.
10. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281-291. (Pubitemid 34976993)
11. Papafaklis MI, Koskinas KC, Chatzizisis YS, Stone PH, Feldman CL. In-vivo assessment of the natural history of coronary atherosclerosis: vascular remodeling and endothelial shear stress determine the complexity of atherosclerotic disease progression. Curr Opin Cardiol. 2010;25:627-638.
12. Selamet Tierney ES, Newburger JW. Are patients with Kawasaki disease at risk for premature atherosclerosis? J Pediatr. 2007;151:225-228. (Pubitemid 47287684)
13. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J; American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114:2710-2738.
14. Noto N, Okada T, Abe Y, Miyashita M, Kanamaru H, Karasawa K, Ayusawa M, Sumitomo N, Mugishima H. Characteristics of earlier atherosclerotic involvement in adolescent patients with Kawasaki disease and coronary artery lesions: Significance of gray scale median on B-mode ultrasound. Atherosclerosis. 2012;222:106-109.
15. McCrindle BW, McIntyre S, Kim C, Lin T, Adeli K. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis? J Pediatr. 2007;151:244-8, 248.e1.
16. Dalla Pozza R, Bechtold S, Urschel S, Kozlik-Feldmann R, Netz H. Subclinical atherosclerosis, but normal autonomic function after Kawasaki disease. J Pediatr. 2007;151:239-243. (Pubitemid 47284132)
17. Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, Fishbein MC, Lehman TJ, Arditi M. Interleukin-1ß is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125:1542-1550.
18. Rosenkranz ME, Schulte DJ, Agle LM, Wong MH, Zhang W, Ivashkiv L, Doherty TM, Fishbein MC, Lehman TJ, Michelsen KS, Arditi M. TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease. Circulation. 2005;112:2966-2973. (Pubitemid 41612299)
19. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004;101:10679-10684. (Pubitemid 38955802)
20. Naiki Y, Sorrentino R, Wong MH, Michelsen KS, Shimada K, Chen S, Yilmaz A, Slepenkin A, Schröder NW, Crother TR, Bulut Y, Doherty TM, Bradley M, Shaposhnik Z, Peterson EM, Tontonoz P, Shah PK, Arditi M. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control ChlaMyDia pneumoniae-induced acceleration of atherosclerosis. J Immunol. 2008;181:7176-7185.
21. Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and ChlaMyDia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol. 2010;185:5619-5627.
22. + T cells in coronary artery lesions in patients with Kawasaki disease. Exp Mol Pathol. 2007;83:93-103. (Pubitemid 46842967)
23. Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol. 2004;173:6366-6375. (Pubitemid 39487796)
24. Baitsch D, Bock HH, Engel T, Telgmann R, Müller-Tidow C, Varga G, Bot M, Herz J, Robenek H, von Eckardstein A, Nofer Jr. Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol. 2011;31:1160-1168.
25. Kelsall BL, Biron CA, Sharma O, Kaye PM. Dendritic cells at the host-pathogen interfACE. Nat Immunol. 2002;3:699-702.
26. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 2001;106:259-262.
27. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255-258. (Pubitemid 32772607)
28. Decker T, Müller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5:675-687. (Pubitemid 43086170)
29. Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science. 2001;293:253-256. (Pubitemid 32694733)
30. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity. 2004;21:733-741. (Pubitemid 39487894)
31. Erbel C, Sato K, Meyer FB, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol. 2007;102:123-132. (Pubitemid 46189953)
32. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic t-cell function in the atherosclerotic plaque through interferon-alpha. Circulation. 2006;114:2482-2489. (Pubitemid 44901521)
33. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
34. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22:361-403. (Pubitemid 38680427)
35. Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, Newburger JW. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124:1-8.
36. Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation. 1991;84:625-631.
37. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics. 1978;61:100-107. (Pubitemid 8268802)
38. Fujiwara T, Fujiwara H, Hamashima Y. Frequency and size of coronary arterial aneurysm at necropsy in Kawasaki disease. Am J Cardiol. 1987;59:808-811. (Pubitemid 17061291)
39. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519. (Pubitemid 43980523)
40. Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 2008;58:2268-2274.
41. Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS, Gelber AC, Ouyang P, Jenny NS, Bathon JM. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum. 2012;41:535-544.
42. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007;56:3412-3419. (Pubitemid 47585436)
43. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399-2406. (Pubitemid 37542988)
44. Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KM, Li H, Castellani LW, Wang X, Iikuni N, Rullo OJ, Wu H, La Cava A, Fogelman AM, Lusis AJ, Tsao BP. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther. 2010;12:R93.
45. Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J. 2008;72:1583-1587.
46. Lehman TJ, Walker SM, Mahnovski V, McCurdy D. Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum. 1985;28:652-659. (Pubitemid 15059076)
47. Lehman TJ, Mahnovski V. Animal models of vasculitis. Lessons we can learn to improve our understanding of Kawasaki disease. Rheum Dis Clin North Am. 1988;14:479-487.
48. Lehman TJ. Can we prevent long term cardiac damage in Kawasaki disease? Lessons from Lactobacillus casei cell wall-induced arteritis in mice. Clin Exp Rheumatol. 1993;11(suppl 9):S3-S6. (Pubitemid 23236144)
49. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218-1226. (Pubitemid 35373552)
50. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev. 2007;219:187-203. (Pubitemid 47390007)
51. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876-1890. (Pubitemid 34219736)
52. Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med. 2009;360:2467-2470.
53. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol. 2010;22:28-33.
54. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656-660. (Pubitemid 36438080)
55. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y, Ohsuzu F. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24:1068-1073. (Pubitemid 38737833)
56. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res. 2005;66:583-593. (Pubitemid 40725770)
57. Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz). 2009;57:165-176.
58. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118-1125.
59. Chamberlain J, Evans D, King A, Dewberry R, Dower S, Crossman D, Francis S. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol. 2006;168:1396-1403.
60. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, FalACE DA, Taubert KA; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-2771. (Pubitemid 39453026)